Session Title: Vascular Diseases & Anterior/posterior segment surgery
Session Date/Time: Sunday 29/09/2013 | 11:00-13:00
Paper Time: 11:00
Venue: Hall 3 (Level 0)
First Author: M.Loutfi UK
Co Author(s): M. Siddiqui A. Dhedhi A. Kamal
This article is a meta-analysis of published literature comparing intravitreal ranibizumab versus bevacizumab for the treatment of myopic choroidal neovascularization.
University of Liverpool
Electronic databases were searched from January 1950 to November 2012.
3 studies reported on 117 patients. The mean number of lines improvement after intravitreal ranibizumab appeared better compared with intravitreal bevacizumab [random effects model: SMD=4.42,95%CI(1.11,7.73),z=2.62,p=0.009]. The number of patients who had a greater than 3 line improvement was similar between groups [fixed effects model: RR=0.95,95%CI(0.67,1.32),z=0.33,p=0.74]. At follow up there was no difference in number of those who had an absence of leakage [fixed effects model: RR=1.05,95%CI(0.94,1.19),z=0.88,p=0.38]. There was no statistical significance between the two groups in relation to the number of injections [random effects model: SMD=0.50,95%CI(-0.16,1.15),z=1.48,p=0.14].
Early evidence suggests intravitreal ranibizumab is comparable to intravitreal bevacizumab in the treatment of myopic choroidal neovascularization. Further studies are required to investigate the finding of overall improvement in the number of lines between groups.